Drug Profile
Research programme: neurodegenerative disease therapeutics - Neuronascent
Alternative Names: NNI-370Latest Information Update: 28 Nov 2019
Price :
$50
*
At a glance
- Originator Neuronascent
- Class Antiparkinsonians; Small molecules
- Mechanism of Action Nerve growth factor stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 28 Nov 2019 No recent reports of development identified for research development in Parkinson's-disease in USA (PO)
- 20 Nov 2017 NNI 370 is still in early research for Parkinson's disease in USA (PO) (Neuronascent pipeline, November 2017)
- 14 Nov 2017 Neuronascent has composition of matter patent protection for oral neuron regenerative technology in Europe